SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2018 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
STRO on Nasdaq
Shares outstanding
84,733,230
Price per share
$11.57
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
53,391,796
Total reported value
$46,361,876
% of total 13F portfolios
0%
Share change
-2,191,668
Value change
-$1,653,951
Number of holders
85
Price from insider filings
$11.57
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Affinity Asset Advisors, LLC 7.8% $5,717,348 6,583,772 Affinity Healthcare Fund, LP 16 Oct 2025
SUVRETTA CAPITAL MANAGEMENT, LLC 7.7% $4,632,014 6,488,324 Suvretta Capital Management, LLC 30 Jun 2025
MILLENNIUM MANAGEMENT LLC 5.6% $4,434,182 4,717,215 Millennium Management LLC 27 Jun 2025
VANGUARD GROUP INC 4.9% $2,937,877 4,115,250 The Vanguard Group 30 Jun 2025
BlackRock, Inc. 2.5% -69% $1,493,679 -$2,892,242 2,092,281 -66% BlackRock, Inc. 30 Jun 2025

As of 30 Sep 2025, 85 institutional investors reported holding 53,391,796 shares of SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO). This represents 63% of the company’s total 84,733,230 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO) together control 59% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
SUVRETTA CAPITAL MANAGEMENT, LLC 7.7% 6,488,324 0% 0.17% $5,634,461
Kynam Capital Management, LP 6% 5,088,099 0% 0.33% $4,418,505
MILLENNIUM MANAGEMENT LLC 5.3% 4,524,350 -4.4% 0% $3,928,946
VANGUARD GROUP INC 4.3% 3,682,986 -11% 0% $3,196,832
ACADIAN ASSET MANAGEMENT LLC 4% 3,389,322 +11% 0.01% $2,941,000
Velan Capital Investment Management LP 3.7% 3,120,000 +2% 2.5% $2,709,408
TANG CAPITAL MANAGEMENT LLC 3.3% 2,828,717 +10% 0.09% $2,456,458
Merck & Co., Inc. 3.2% 2,723,509 0% 1% $2,365,095
Vestal Point Capital, LP 3.1% 2,600,000 0% 0.1% $2,257,840
Eversept Partners, LP 2.7% 2,291,313 -0.04% 0.15% $1,989,776
SAMSARA BIOCAPITAL, LLC 2.6% 2,196,814 0% 0.25% $1,907,713
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.4% 2,000,000 0% 0% $1,736,800
UBS Group AG 2.2% 1,845,839 +14% 0% $1,602,188
BlackRock, Inc. 2% 1,687,880 -20% 0% $1,465,755
RENAISSANCE TECHNOLOGIES LLC 1.7% 1,424,797 +56% 0% $1,237,294
GEODE CAPITAL MANAGEMENT, LLC 0.97% 820,948 +0.49% 0% $713,188
Affinity Asset Advisors, LLC 0.89% 752,722 0% 0.06% $653,664
JACOBS LEVY EQUITY MANAGEMENT, INC 0.53% 445,750 0% $387,089
DAFNA Capital Management LLC 0.52% 437,079 0% 0.09% $379,559
TWO SIGMA INVESTMENTS, LP 0.47% 396,785 +245% 0% $344,568
AQR CAPITAL MANAGEMENT LLC 0.42% 354,449 -65% 0% $307,804
Fisher Asset Management, LLC 0.42% 352,949 0% 0% $306,500
STATE STREET CORP 0.4% 342,652 0% 0% $297,559
Shay Capital LLC 0.37% 312,051 +20% 0.05% $270,985
ROYAL BANK OF CANADA 0.31% 258,876 +17% 0% $225,000

Institutional Holders of SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 56 $648 -$77,585 $11.57 1
2025 Q3 53,391,796 $46,361,876 -$1,653,951 $0.87 85
2025 Q2 55,585,121 $39,680,994 -$3,651,726 $0.71 100
2025 Q1 61,457,334 $39,985,859 -$10,841,219 $0.65 113
2024 Q4 63,895,959 $117,565,386 -$7,306,459 $1.84 122
2024 Q3 62,516,525 $216,373,636 -$1,660,759 $3.46 130
2024 Q2 63,167,394 $185,075,042 +$25,139,079 $2.93 119
2024 Q1 53,412,221 $301,719,025 +$2,094,339 $5.65 116
2023 Q4 55,648,249 $238,729,642 -$219,480 $4.29 113
2023 Q3 55,996,442 $194,308,615 +$5,622,550 $3.47 108
2023 Q2 54,105,078 $251,585,717 +$2,181,872 $4.65 119
2023 Q1 53,720,779 $247,499,715 +$10,470,599 $4.62 114
2022 Q4 49,984,035 $403,859,817 +$6,296,600 $8.08 116
2022 Q3 50,396,383 $279,697,401 +$23,514,794 $5.55 111
2022 Q2 46,245,672 $240,931,373 +$15,713,924 $5.21 111
2022 Q1 41,606,389 $341,990,813 -$38,514,469 $8.22 111
2021 Q4 39,677,298 $590,411,817 -$4,363,219 $14.88 114
2021 Q3 39,817,120 $752,214,523 -$26,368,206 $18.89 119
2021 Q2 41,241,047 $766,657,023 -$71,886,996 $18.59 121
2021 Q1 44,209,991 $1,005,487,689 +$114,863,310 $22.76 136
2020 Q4 39,392,744 $855,224,796 +$184,675,658 $21.71 132
2020 Q3 31,151,440 $313,088,624 +$67,545,691 $10.05 87
2020 Q2 23,997,579 $186,238,799 +$97,614,730 $7.76 76
2020 Q1 11,868,607 $116,270,683 +$7,872,102 $10.20 60
2019 Q4 11,616,437 $127,772,633 +$7,088,075 $11.00 64
2019 Q3 11,074,608 $91,621,057 -$8,301,817 $9.09 59
2019 Q2 11,817,484 $122,739,770 +$6,666,665 $11.38 58
2019 Q1 11,231,778 $116,185,606 +$4,727,906 $11.39 49
2018 Q4 9,707,399 $87,234,000 -$10,616,486 $9.02 41
2018 Q3 9,086,875 $135,767,000 +$129,306,000 $15.00 32